Page last updated: 2024-08-22

tiletamine hydrochloride and Cardiomyopathies

tiletamine hydrochloride has been researched along with Cardiomyopathies in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chattipakorn, N; Chen, X; Feng, J; Guan, X; Jin, L; Liang, G; Luo, W; Pavlov, VN; Samorodov, AV; Wang, M; Wang, Y; Yang, D; Ye, L; Zhuang, Z1
Arora, N; Kelly, DA; McKiernan, PJ; Stumper, O; Wright, J1

Other Studies

2 other study(ies) available for tiletamine hydrochloride and Cardiomyopathies

ArticleYear
Curcumin analogue C66 attenuates obesity-induced myocardial injury by inhibiting JNK-mediated inflammation.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 143

    Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Benzylidene Compounds; Cardiomyopathies; Cell Line; Cyclohexanones; Cytokines; Diet, High-Fat; Disease Models, Animal; JNK Mitogen-Activated Protein Kinases; Male; Mice, Inbred C57BL; Myocarditis; Myocytes, Cardiac; NF-kappa B; Obesity; Palmitic Acid; Rats; Signal Transduction

2021
Cardiomyopathy in tyrosinaemia type I is common but usually benign.
    Journal of inherited metabolic disease, 2006, Volume: 29, Issue:1

    Topics: Adolescent; Cardiomyopathies; Child; Child, Preschool; Cyclohexanones; Echocardiography; Enzyme Inhibitors; Female; Humans; Infant; Infant, Newborn; Male; Nitrobenzoates; Retrospective Studies; Treatment Outcome; Tyrosinemias

2006